ClinicalTrials.gg

Program

ensitrelvir

Also written as “S-217622” and “Ensitrelvir”.

Its studies are mostly in COVID-19 · Renal Insufficiency, led by Shionogi.

Furthest: phase 3, since Mar 30, 20225 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi50 open or runningphase 3since Mar 30, 2022Mar 30, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2022First study: phase 3 study in COVID-19First studyNCT05305547 · 2,093 enrolled · United States, Argentina, Brazil and more
  2. May 3, 2022Phase 1 study in Renal InsufficiencyNCT05363215 · 32 enrolled · United States
  3. Jun 3, 2022Phase 1 study in Hepatic ImpairmentNCT05409911 · 25 enrolled · United States
  4. Jun 6, 2023Phase 3 study in COVID-19NCT05897541 · 3,701 enrolled · United States, Argentina, Japan and more
  5. Jan 9, 2025Phase 1 study in Healthy Adult Female ParticipantsNCT06775730 · 24 enrolled · United States

TargetBeta

SERPINA1 →read by rule
“This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&;”study text, by rule · the study

Other programs on SERPINA1

ProgramCompanyFurthest phaseStudies
efdoralprin alfaSanofiphase 22
CTX460rulecrispr-therapeuticsphase 21
Proteasome Inhibitor SHY-ONC6ruleshy-therapeuticsphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06775730Healthy Adult Female Participants · United States1CompletedApr 3, 202524
NCT05897541COVID-19 · United States, Argentina, Japan and more3CompletedAug 30, 20243,701
NCT05409911Hepatic Impairment · United States1CompletedApr 25, 202325
NCT05363215Renal Insufficiency · United States1CompletedApr 12, 202332
NCT05305547COVID-19 · United States, Argentina, Brazil and more3CompletedJan 7, 20242,093

How it is read

Names in the registry

  • “S-217622”, 4 entries
  • “Ensitrelvir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.